Performance Determinants Factors in Elite Endurance Athletes.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03569566|
Recruitment Status : Enrolling by invitation
First Posted : June 26, 2018
Last Update Posted : April 9, 2019
|Condition or disease||Intervention/treatment|
|Exercise Physiology||Other: Age, Genes, Training, Tickbourne Disease and Endurance|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||The Impact of Age, Genes, Training and History of Tickbourne Disease on Endurance Performance in Elite Endurance Athletes.|
|Actual Study Start Date :||June 27, 2018|
|Estimated Primary Completion Date :||December 2020|
|Estimated Study Completion Date :||December 2021|
Elite endurance athletes
Cross-country skiers at high national level
Other: Age, Genes, Training, Tickbourne Disease and Endurance
Testing of genes, exosomes, physiological variables, tick-bourne disease markers, observation of training modality and performance
- Time trail cross-country roller skiing performance [ Time Frame: Change from baseline performance at 3-months and at 6-months ]Testing of seconds used in a predefined track
- Maximal oxygen consumption [ Time Frame: Change from baseline maximal oxygen uptake at 3-months and at 6-months ]Standard ergospirometrical incremental test in running and double-poling
- Lactate threshold in double poling [ Time Frame: Change from baseline lactate threshold at 3-months and at 6-months ]Onset of blood lactate accumulation in an incremental interval protocol
- Double poling economy [ Time Frame: Change from baseline economy at 3-months and at 6-months ]Ergospirometrical measurement of oxygen consumption per meter poling
- Maximal strength [ Time Frame: Change from baseline maximal strength at 3-months and at 6-months ]Kilograms measured in one repetition maximum in half-squat and pull-down
- Jump height [ Time Frame: Change from baseline jump height at 3-months and at 6-months ]Centimeters measured on force platform in squat jump, counter movement jump and countermovement jump with armswing
- Genotypes [ Time Frame: Baseline ]Distribution of alleles for candidate genes derrived from blood samples
- Tick-bourne disease [ Time Frame: Baseline ]Blood markers for previous tick-bourne disease
- Exosomes [ Time Frame: Baseline ]Quantifying number of exosomes in blood immediately before and after maximal aerobic work and maximal strength tests
- Training volume [ Time Frame: Change from baseline training volume at 3-months and at 6-months ]Registration of training volume in hours from training diaries
- Training intensity [ Time Frame: Change from baseline training intensity at 3-months and at 6-months ]Registration of training intensity by use of heart rate measures corresponding to the training intensity scale made by the Norwegian Olympic Sports Center.
- Age [ Time Frame: Baseline ]Age in years
- Maximal power [ Time Frame: Change from baseline power at 3-months and at 6-months ]Maximal power in watt in half-squat and pull-down
Biospecimen Retention: Samples With DNA
Blood samples will be taken, and will be used for the following purposes:
- DNA isolation and analysis: DNA genome will be isolated from white blood cells. This DNA genome will be contained in a biobank - Exercise Genetics. Well-known genetic variations in genes will be tested showing relevance to training adaptations (ACE, ACTN3 etc.). Only known polymorphisms will be investigated.
- Exosome isolation from plasma: We will isolate exosomes from plasma by the ultracentrifugation method. We will investigate the volume and specific types of exosomes, in relation to the training intervention. We also want to examine the exosome-cargo, like miRNA, protein content, mRNA and DNA content.
- Isolation of antibodies from plasma: We want to investigate antibodies to examine potential on-going disease, recently disease or earlier disease of Barbesia, Anaplasma or other actual tick-borne agens. We also want to isolate DNA from blood and use real-time PCR for anaplasma and Neo Ehrlichia analysis.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03569566
|Telemark University College|
|Bø, Telemark, Norway, 3800|
|Study Chair:||Pål Augestad, PhD||Telemark University College|